Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis

Liver International

Volumn 34, Issue 5, 2014, Pages 679-688

  Aiba, Yoshihiro ^a   Harada, Kenichi ^b   Komori, Atsumasa ^a,c   Ito, Masahiro ^a,c   Shimoda, Shinji ^d   Nakamura, Hitomi ^a   Nagaoka, Shinya ^a   Abiru, Seigo ^a   Migita, Kiyoshi ^a,c   Ishibashi, Hiromi ^e   Nakanuma, Yasuni ^b   Nishida, Nao ^f   Kawashima, Minae ^f   Tokunaga, Katsushi ^f   Yatsuhashi, Hiroshi ^a,c   Nakamura, Minoru ^a,c,g  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Decoy receptor 3; Primary biliary cirrhosis; Tumour necrosis factor like ligand 1A; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; BEZAFIBRATE; DECOY RECEPTOR 3; IMMUNOGLOBULIN M; MESSENGER RNA; NEOMINOPHAGEN C; PEGINTERFERON ALPHA; PREDNISOLONE; TL1A PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CHOLAGOGUE; TNFRSF6B PROTEIN, HUMAN; TNFSF15 PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTRAHEPATIC BILE DUCT; KUPFFER CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIMARY BILIARY CIRRHOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; AGED; BLOOD; CASE CONTROL STUDY; LIVER; LIVER CIRRHOSIS, BILIARY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; URSODEOXYCHOLIC ACID;

EID: 84897958239     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12296     Document Type: Article

References (47)

1. Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360: 2544-55.
2. Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010; 42: 655-7.
3. Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010; 42: 658-60.
4. Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011; 43: 329-32.
5. Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012; 91: 721-8.
6. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-92.
7. Cassatella MA, Pereira-da-Silva G, Tinazzi I, et al. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 2007; 178: 7325-33.
8. Shih DQ, Kwan LY, Chavez V, et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 2009; 39: 3239-50.
9. Yue TL, Ni J, Romanic AM, et al. TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 1999; 274: 1479-86.
10. Haridas V, Shrivastava A, Su J, et al. VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 1999; 18: 6496-504.
11. Bayry J. Immunology: TL1A in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 2010; 6: 67-8.
12. Bamias G, Kaltsa G, Siakavellas SI, et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010; 137: 242-9.
13. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003; 171: 4868-74.
14. Bamias G, Siakavellas SI, Stamatelopoulos KS, et al. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol 2008; 129: 249-55.
15. Bamias G, Evangelou K, Vergou T, et al. Upregulation and nuclear localization of TNF-like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol 2011; 20: 725-31.
16. Bull MJ, Williams AS, Mecklenburgh Z, et al. The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008; 205: 2457-64.
17. Pappu BP, Borodovsky A, Zheng TS, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008; 205: 1049-62.
18. Meylan F, Davidson TS, Kahle E, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008; 29: 79-89.
19. Bamias G, Mishina M, Nyce M, et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA 2006; 103: 8441-6.
20. Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135: 552-67.
21. Lee CS, Hu CY, Tsai HF, et al. Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus. Clin Exp Immunol 2008; 151: 383-90.
22. Wu Y, Han B, Sheng H, et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003; 105: 724-32.
23. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 2001; 61: 2759-65.
24. Ge Z, Sanders AJ, Ye L, et al. Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer. Exp Ther Med 2011; 2: 167-72.
25. Chang YC, Hsu TL, Lin HH, et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004; 75: 486-94.
26. Hsu TL, Chang YC, Chen SJ, et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 2002; 168: 4846-53.
27. Huang ZM, Kang JK, Chen CY, et al. Decoy receptor 3 suppresses TLR2-mediated B cell activation by targeting NF-kappaB. J Immunol 2012; 188: 5867-76.
28. Funke B, Autschbach F, Kim S, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009; 58: 483-91.
29. Kim S, McAuliffe WJ, Zaritskaya LS, et al. Selective induction of tumor necrosis receptor factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells. Infect Immun 2004; 72: 89-93.
30. Chen J, Zhang L, Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004; 285: 63-70.
31. Wang YL, Chou FC, Sung HH, et al. Decoy receptor 3 protects non-obese diabetic mice from autoimmune diabetes by regulating dendritic cell maturation and function. Mol Immunol 2010; 47: 2552-62.
32. Sung HH, Juang JH, Lin YC, et al. Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 2004; 199: 1143-51.
33. Ka SM, Hsieh TT, Lin SH, et al. Decoy receptor 3 inhibits renal mononuclear leukocyte infiltration and apoptosis and prevents progression of IgA nephropathy in mice. Am J Physiol Renal Physiol 2011; 301: F1218-30.
34. Ka SM, Sytwu HK, Chang DM, et al. Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice. J Am Soc Nephrol 2007; 18: 2473-85.
35. Han B, Moore PA, Wu J, et al. Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome. Arthritis Rheum 2007; 56: 3748-58.
36. Silveira MG, Brunt EM, Heathcote J, et al. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010; 52: 349-59.
37. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118-27.
38. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
39. Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010; 60: 167-74.
40. Takii Y, Nakamura M, Ito M, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest 2005; 85: 908-20.
41. Harada K, Van de Water J, Leung PS, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. Hepatology 1997; 25: 791-6.
42. Bamias G, Kaltsa G, Siakavellas SI, et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis 2012; 44: 30-6.
43. Yokoyama T, Komori A, Nakamura M, et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and -MAPK signaling pathways. Liver Int 2006; 26: 467-76.
44. Shimoda S, Harada K, Niiro H, et al. Biliary epithelial cells and primary biliary cirrhosis: the role of liver-infiltrating mononuclear cells. Hepatology 2008; 47: 958-65.
45. Harada K, Shimoda S, Sato Y, et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009; 157: 261-70.
46. Chen SJ, Wang YL, Kao JH, et al. Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells. Mol Immunol 2009; 47: 567-74.
47. Chen CY, Yang KY, Chen MY, et al. Decoy receptor 3 levels in peripheral blood predict outcomes of acute respiratory distress syndrome. Am J Respir Crit Care Med 2009; 180: 751-60.